Glucagon Human ELISA (Multispecies specificity)
According to many studies on glucagon immunoassay, it has been established that the antibody against the C – terminal fragment ( 19 – 29 ) of glucagon has specific binding with pancreatic glucagon, whereas the antibody against the N – terminal fragment ( 9 – 19 ) of glucagon has specific binding with both of pancreatic and intestinal glucagon ( total glucagon ). Once, 30K by Unger et. al had been widely used as an antibody specific for the C – terminal fragment of glucagon, but Nishino, Shima and Yanaihara et. al succeeded in producing pancreatic glucagon specific antibody using synthetic peptide with the C – terminal fragment ( 19 – 29 ) of glucagon as
immunogen in 1981.
This EIA kit has been developed by using polyclonal antibody against glucagon ( 19 – 29 ), synthetic glucagon as standard antigen and biotinylated glucagon as labeled antigen for the measurment of rat, mouse or human glucagon in plasma.
Research topic
Animal studies, Diabetology – Other Relevant Products
Type
Competitive ELISA, Immobilized antibody
Applications
Plasma
Sample Requirements
50 µl or 100 µl/well
Storage/Expiration
Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).
Calibration Curve
Calibration Range
50–10 000 pg/ml
– Salis ER, Reith DM, Wheeler BJ, Broadbent RS, Medlicott NJ. Insulin resistance, glucagon-like peptide-1 and factors influencing glucose homeostasis in neonates. Arch Dis Child Fetal Neonatal . 2016 Sep 2;